<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03568981</url>
  </required_header>
  <id_info>
    <org_study_id>4-2018-0160</org_study_id>
    <nct_id>NCT03568981</nct_id>
  </id_info>
  <brief_title>Impact of 5-fraction Stereotactic Partial Breast Irradiation and Whole Breast Irradiation on Cosmetic Outcome and Patient-reported Outcomes in Early-stage Breast Cancer</brief_title>
  <official_title>Impact of 5-fraction Stereotactic Partial Breast Irradiation and Whole Breast Irradiation on Cosmetic Outcome and Patient-reported Outcomes in Early-stage Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aim to investigate the effect of 5-fraction stereotactic partial breast
      irradiation and whole breast irradiation on patient-reported outcomes, cosmetic outcome, and
      breast tissue fibrosis in early-stage breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 11, 2018</start_date>
  <completion_date type="Anticipated">April 11, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 11, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change of patient reported psychosocial functioning score</measure>
    <time_frame>Before radiotherapy (allowed to 8 weeks before radiotherapy)</time_frame>
    <description>Patient reported psychosocial functioning measured in 7 point Likert scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of patient reported psychosocial functioning score</measure>
    <time_frame>2 year after radiotherapy (allowed to plus 8 weeks)</time_frame>
    <description>Patient reported psychosocial functioning measured in 7 point Likert scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of patient reported patient treatment satisfaction score</measure>
    <time_frame>Before radiotherapy (allowed to 8 weeks before radiotherapy)</time_frame>
    <description>Patient reported patient treatment satisfaction measured in 7 point Likert scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of patient reported patient treatment satisfaction score</measure>
    <time_frame>2 year after radiotherapy (allowed to plus 8 weeks)</time_frame>
    <description>Patient reported patient treatment satisfaction measured in 7 point Likert scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of patient reported physical functioning score</measure>
    <time_frame>Before radiotherapy (allowed to 8 weeks before radiotherapy)</time_frame>
    <description>Patient reported physical functioning measured in 7 point Likert scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of patient reported physical functioning score</measure>
    <time_frame>2 year after radiotherapy (allowed to plus 8 weeks)</time_frame>
    <description>Patient reported physical functioning measured in 7 point Likert scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of patient reported body image score</measure>
    <time_frame>Before radiotherapy (allowed to 8 weeks before radiotherapy)</time_frame>
    <description>Patient reported body image score measured in 7 point Likert scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of patient reported body image score</measure>
    <time_frame>2 year after radiotherapy (allowed to plus 8 weeks)</time_frame>
    <description>Patient reported body image score measured in 7 point Likert scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of breast cosmesis measures (excellent/good/poor)</measure>
    <time_frame>Before radiotherapy (allowed to 8 weeks before radiotherapy</time_frame>
    <description>breast cosmesis result is measures by BCCT.core (Breast Cancer Conservative Treatment cosmetic results) software
- Investigators will whether there are any changes on patient-reported outcomes, cosmetic outcome, and breast tissue fibrosis after radiotherapy. Any differences of theses parameters according to the radiotherapy techniques (PBI vs. WBI) will be examed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of breast cosmesis measures (excellent/good/poor)</measure>
    <time_frame>2 year after radiotherapy (allowed to plus 8 weeks)</time_frame>
    <description>breast cosmesis result is measures by BCCT.core (Breast Cancer Conservative Treatment cosmetic results) software</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of breast-tissue fibrosis measures (gram)</measure>
    <time_frame>Before radiotherapy (allowed to 8 weeks before radiotherapy</time_frame>
    <description>breast-tissue fibrosis is measured by tissue compliance meter device.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of breast-tissue fibrosis measures (gram)</measure>
    <time_frame>2 year after radiotherapy (allowed to plus 8 weeks)</time_frame>
    <description>breast-tissue fibrosis is measured by tissue compliance meter device.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Radiotherapy-related complications</measure>
    <time_frame>Before radiotherapy (allowed to 8 weeks before radiotherapy)</time_frame>
    <description>Investigators will check whether there are any kinds of radiotherapy-related complications after PBI or WBI. Any differences of complications according to the radiotherapy techniques will be examed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Radiotherapy-related complications</measure>
    <time_frame>2 year after radiotherapy (allowed to plus 8 weeks)</time_frame>
    <description>Investigators will check whether there are any kinds of radiotherapy-related complications after PBI or WBI. Any differences of complications according to the radiotherapy techniques will be examed.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Partial Breast Irradiation (PBI)</arm_group_label>
    <description>Patients receiving 5-fraction stereotactic partial breast irradiation for breast cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Whole Breast Irradiation (WBI)</arm_group_label>
    <description>Patients receiving whole breast irradiation for breast cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Partial breast irradiation</intervention_name>
    <description>After breast- conservating surgery, all patients are allowed to receive partial breast irradiation or whole breast irradiation after surgery according to the international guidelines and physician's discretion.</description>
    <arm_group_label>Partial Breast Irradiation (PBI)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Whole breast irradiation</intervention_name>
    <description>After breast- conservating surgery, all patients are allowed to receive partial breast irradiation or whole breast irradiation after surgery according to the international guidelines and physician's discretion.</description>
    <arm_group_label>Whole Breast Irradiation (WBI)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women undergoing radiotherapy after breast-conservating surgery at an academic center
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically confirmed invasive breast carcinoma or ductal carcinoma in situ (DCIS)

          -  Women who underwent breast-conservating surgery and have a plan to undergoing partial
             or whole breast irradiation

          -  Good performance status (ECOG 0-1)

        Exclusion Criteria:

          -  Recurrent breast cancer

          -  History of ipsilateral breast irradiation

          -  Positive resection margin status after breast surgery
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Women undergoing radiotherapy after breast-conservating surgery at an academic center</gender_description>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yong Bae Kim, MD, PhD</last_name>
    <phone>82-2228-8095</phone>
    <email>ybkim3@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>YongBae Kim, MD</last_name>
      <phone>82-10-6256-2592</phone>
      <email>ybkim3@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>May 15, 2018</study_first_submitted>
  <study_first_submitted_qc>June 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2018</study_first_posted>
  <last_update_submitted>June 13, 2018</last_update_submitted>
  <last_update_submitted_qc>June 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

